This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

April 15, 2022

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL:https://www.modalistx.com/en/

Representative: Haruhiko Morita

Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)

Modalis Therapeutics Corporation (hereafter, "the Company") hereby announces that the pending terms and conditions of the share acquisition rights, to be issued as part of the Company's stock option program pursuant to the Board of Directors' resolution dated March 29, 2022 have been determined as follows:

1．Exercise price of stock acquisition rights

  • (1) Value of the Asset to be Contributed upon Exercise of Share Acquisition Rights 36,500 yen per one unit of Share Acquisition Rights (365 yen per share)

  • (2) Calculation Method of Exercise Price

    The Exercise Price shall be the higher of either the amount obtained by multiplying the average closing price of shares of the common stock of the Company on the Tokyo Stock Exchange on each day (excluding days on which there is no trading) of the month immediately preceding the month in which the Share Acquisition Rights will be issued by 1.05 or the closing price of shares of the common stock of the Company on the Tokyo Stock Exchange on the day of allotment of the Share Acquisition Rights (if there is no trading on the day, the closing price on the immediately preceding day shall be used).

2．Number of the Rights

The number of the Rights to be issued shall 300 units. （The number of units per Rights shall be 100 shares.）

3．The class and number of shares to be issued upon exercising the Rights

The type of shares shall be 30,000 shares of the Company's common stock.

4．Persons to whom Share Acquisition Rights are Allocated, the Number of such Persons, and the Number of Share

Acquisition Rights Allocated

Company's Directors (excluding directors 2 Persons 300 units（30,000 shares）

who are members of the Audit Committee)

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Modalis Therapeutics Corporation published this content on 15 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 April 2022 07:49:01 UTC.